Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

Clinical trial NCT05910970 · UNKNOWN

Trial details

NCT number: NCT05910970
Sponsor: Guangxi Medical University
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Recurrence Immune Checkpoint Inhibitor

Start date: 2024-02-15
Primary completion: 2025-12-31
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.